The Effect of Good Bacteria on Nonalcoholic Fatty Liver Disease in Diabetics
Status and phase
Conditions
Treatments
Details and patient eligibility
About
The purpose of this study is to determine whether probiotics, bacteria that may improve liver health, can effectively treat a chronic condition in diabetics that increases fat in the liver.
Full description
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States and is also common in diabetics; unfortunately, research on NAFLD has been limited. Safe, inexpensive, and well-tolerated treatments for NAFLD are needed. Recent studies indicate that probiotics help to improve fat breakdown in mice. This study will evaluate the efficacy of probiotic therapy to reduce fat accumulation in the livers of people with NAFLD and diabetes.
Participants in this study will be randomly assigned to receive either a probiotic-containing mixture or placebo once daily for 6 months. Blood tests, and magnetic resonance spectroscopy will be used to assess participants at study start and at study completion.
Sex
Ages
Volunteers
Inclusion criteria
- Nonalcoholic fatty liver disease
Exclusion criteria
- Any cause of liver disease other than hepatic steatosis
- Diabetes
- Known or suspected cirrhosis
- Inability or unwillingness to undergo magnetic resonance procedures
- Requirement of long-term antibiotic therapy
- Pregnancy, breast-feeding, or plans to become pregnant
Trial design
Primary purpose
Allocation
Interventional model
Masking
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal